Metabolic Cost of Kettlebell Training

December 18, 2023 updated by: Dimitrios Draganidis, University of Thessaly
This study aims at investigating the metabolic cost of several fundamental exercises with Kettlebell. Kettlebell training has become a popular training modality that is efficiently used to improve cardiovascular status and physical performance. Despite its widespread use and popularity the metabolic cost of exercises using kettlebell remains to be elucidated. Therefore, the metabolic cost of various fundamental exercise with kettlebell will be determined to aid the planning of exercise training programs.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Ten healthy young adults will be assigned to this study. Participants will initially undergo a baseline assessment of their anthropometrics, body composition (by DXA), resting metabolic rate (RMR), cardiorespiratory fitness (VO2max), muscular strength [maximal strength (1RM) and muscular endurance] and functional capacity. After baseline screening, participants will execute in different days (one exercise per day) one set of each of the following 7 exercises: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch, in two different conditions: (i) 30 sec and (ii) 45 sec exercise duration, in a random order. Prior to each exercise resting heart rate, blood lactate concentration, oxygen consumption and rate of perceived exertion will be recorded. Heart rate and oxygen consumption (through portable gas analyzer) will be continuously monitored during the exercise and after the end of it, until the oxygen consumption reach the pre-exercise values (excess post-exercise oxygen consumption). Blood lactate and rate of perceived exertion will be reassessed post-exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Greece
    • Karyes
      • Trikala, Karyes, Greece, 42100
        • Laboratory of Exercise Physiology, Exercise Biochemistry and Sports Nutrition, Department of Physical Education and Sport Science, University of Thessaly

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18-35 years
  • Physically active individuals
  • Free of chronic diseases
  • Free of musculoskeletal injuries
  • Nonsmokers

Exclusion Criteria:

  • Chronic disease
  • Musculoskeletal injury
  • Consumption of alcohol, caffeine and any type of ergogenic supplement during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 30-SEC
Participants will execute each exercise for 30 seconds
Other: Kettlebell exercise
Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
Experimental: 45-SEC
Participants will execute each exercise for 45 seconds
Other: Kettlebell exercise
Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in exercise energy expenditure
Time Frame: At pre-exercise, during and up to 15 minutes after the exercise (a single set lasting 30 or 45 seconds)
Total energy expenditure (kcals) during the exercise will be assessed by summing the kcals of the oxidative system, the glycolytic system and the excess post-exercise oxygen consumption.
At pre-exercise, during and up to 15 minutes after the exercise (a single set lasting 30 or 45 seconds)
Change in aerobic energy expenditure
Time Frame: At pre-exercise and during the exercise (a single set lasting 30 or 45 seconds)
The contribution of oxidative system in exercise energy expenditure will be assessed by the change in oxygen consumption during the exercise using a portable gas analyzer.
At pre-exercise and during the exercise (a single set lasting 30 or 45 seconds)
Change in anaerobic energy expenditure
Time Frame: At pre-exercise and post-exercise (a single set lasting 30 or 45 seconds)
The contribution of glycolytic system to exercise energy expenditure will be assessed by the change in blood lactate concentration after the exercise
At pre-exercise and post-exercise (a single set lasting 30 or 45 seconds)
Change in recovery energy expenditure
Time Frame: At pre-exercise and up to 15 minutes after the exercise (a single set lasting 30 or 45 seconds)
The contribution of excess post-exercise oxygen consumption in exercise energy expenditure will be assessed by the change in oxygen consumption after the exercise using a portable gas analyzer
At pre-exercise and up to 15 minutes after the exercise (a single set lasting 30 or 45 seconds)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in blood lactate concentration
Time Frame: At pre-exercise and 4 minutes after the exercise session
Blood lactate concentration will be assessed using a portable analyzer
At pre-exercise and 4 minutes after the exercise session
Change in heart rate
Time Frame: At pre-exercise, during and up to 15 minutes after the exercise session.
Heart rate will be continuously monitored using a wearable heart rate monitor
At pre-exercise, during and up to 15 minutes after the exercise session.
Change in rate of perceived exertion
Time Frame: At pre-exercise and post-exercise session.
Rate of perceived exertion will be assessed using the Borg scale (0-10)
At pre-exercise and post-exercise session.
Change in respiratory exchange ratio
Time Frame: At pre-exercise, during and up to 15 minutes after the exercise session.
Respiratory exchange ratio will be assessed using a portable gas analyzer
At pre-exercise, during and up to 15 minutes after the exercise session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Thessaly

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Dimitrios Draganidis, PhD, University of Thessaly

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 15, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 15, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 6, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 6, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 12, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 19, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 18, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MET-KETTLEBELL-UTH

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings